Condition: COPD Asthma
Intervention:
Sponsor: Clalit Health Services
Recruiting – verified December 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Identifying Barriers and Strategies to Support Self-efficacy for Medication Adherence With Text Messaging
Condition: Sickle Cell Disease
Intervention: Other: Interviews and Surveys
Sponsor: Vanderbilt University
Recruiting – verified May 2016
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Identifying Mutations of the Tetratricopeptide Repeat Domain 37 (TTC37) Gene in Infants With Intractable Diarrhea and a Comparison of Asian and Non-Asian Phenotype and Genotype: A Global Case-report Study of a Well-Defined Syndrome With Immunodeficiency.
 |
Related Articles |
Identifying Mutations of the Tetratricopeptide Repeat Domain 37 (TTC37) Gene in Infants With Intractable Diarrhea and a Comparison of Asian and Non-Asian Phenotype and Genotype: A Global Case-report Study of a Well-Defined Syndrome With Immunodeficiency.
Medicine (Baltimore). 2016 Mar;95(9):e2918
Authors: Lee WI, Huang JL, Chen CC, Lin JL, Wu RC, Jaing TH, Ou LS
Abstract
Syndromic diarrhea/tricho-hepato-enteric syndrome (SD/THE) is a rare, autosomal recessive and severe bowel disorder mainly caused by mutations in the tetratricopeptide repeat domain 37 (TTC37) gene which act as heterotetrameric cofactors to enhance aberrant mRNAs decay. The phenotype and immune profiles of SD/THE overlap those of primary immunodeficiency diseases (PIDs).Neonates with intractable diarrhea underwent immunologic assessments including immunoglobulin levels, lymphocyte subsets, lymphocyte proliferation, superoxide production, and IL-10 signaling function. Candidate genes for PIDs predisposing to inflammatory bowel disease were sequencing in this study.Two neonates, born to nonconsanguineous parents, suffered from intractable diarrhea, recurrent infections, and massive hematemesis from esopharyngeal varices due to liver cirrhosis or accompanying Trichorrhexis nodosa that developed with age and thus guided the diagnosis of SD/THE compatible to TTC37 mutations (homozygous DelK1155H, Fs*2; heterozygous Y1169Ter and InsA1143, Fs*3). Their immunologic evaluation showed normal mitogen-stimulated lymphocyte proliferation, superoxide production, and IL-10 signaling, but low IgG levels, undetectable antibody to hepatitis B surface antigen and decreased antigen-stimulated lymphocyte proliferation. A PubMed search for bi-allelic TTC37 mutations and phenotypes were recorded in 14 Asian and 12 non-Asian cases. They had similar presentations of infantile onset refractory diarrhea, facial dysmorphism, hair anomalies, low IgG, low birth weight, and consanguinity. A higher incidence of heart anomalies (8/14 vs 2/12; P?=?0.0344, Chi-square), nonsense mutations (19 in 28 alleles), and hot-spot mutations (W936Ter, 2779-2G>A, and Y1169Ter) were found in the Asian compared with the non-Asian patients. Despite immunoglobulin therapy in 20 of the patients, 4 died from liver cirrhosis and 1 died from sepsis.Patients of all ethnicities with SD/THE with the characteristic triad of T nodosa, hepatic cirrhosis, and intractable enteropathy have low IgG, poor vaccine response and/or decreased antigen-stimulated lymphocyte proliferation. This is now better classified into the subgroup of “well-defined syndromes with immunodeficiency” (the update termed as “combined immunodeficiencies with associated or syndromic features”) than “predominantly antibody deficiencies” in the update PIDs classification, and requires optimal interventions.
PMID: 26945392 [PubMed – in process]
View full post on pubmed: asthma
Asthma – Identifying and Commercializing First-in-Class InnovationAsthma … – Medgadget.com (blog)
|
Asthma – Identifying and Commercializing First-in-Class InnovationAsthma …
Medgadget.com (blog) Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing … |
View full post on asthma – Google News
Frontier Pharma: Asthma – Identifying and Commercializing First-in-Class … – Medgadget.com (blog)
Medgadget.com (blog) |
Frontier Pharma: Asthma – Identifying and Commercializing First-in-Class …
Medgadget.com (blog) Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing … |
View full post on asthma – Google News
Frontier Pharma: Asthma – Identifying and Commercializing First-in-Class … – PR Newswire (press release)
|
Frontier Pharma: Asthma – Identifying and Commercializing First-in-Class …
PR Newswire (press release) Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing … |
View full post on asthma – Google News
Asthma – Identifying and Commercializing First-in-Class Innovation by Market … – Medgadget.com (blog)
|
Asthma – Identifying and Commercializing First-in-Class Innovation by Market …
Medgadget.com (blog) Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing … |
View full post on asthma – Google News
Research and Markets: Frontier Pharma: Asthma – Identifying and … – Business Wire (press release)
|
Research and Markets: Frontier Pharma: Asthma – Identifying and …
Business Wire (press release) Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing … |
View full post on asthma – Google News
Identifying barriers to chronic disease reporting in Chicago Public Schools: a mixed-methods approach.
 |
Related Articles |
Identifying barriers to chronic disease reporting in Chicago Public Schools: a mixed-methods approach.
BMC Public Health. 2014 Dec 6;14(1):1250
Authors: Rivkina V, Tapke DE, Cardenas LD, Harvey-Gintoft B, Whyte SA, Gupta RS
Abstract
BACKGROUND: Chronic disease among school-aged children is a public health concern, particularly for asthma and food allergy. In Chicago Public Schools (CPS), rates of asthma and food allergy among students are underreported. The aim of this study was to determine the barriers to chronic disease reporting as experienced by CPS parents and school nurses.
METHODS: A mixed-methods approach included focus groups and key informant interviews with parents and school nurses, and a cross-sectional survey was completed by parents. Qualitative data analysis was performed and survey data were analyzed to determine the significant demographic and knowledge variables associated with successfully completing the reporting process.
RESULTS: The three main barriers identified were 1) a lack of parental process knowledge; 2) limited communication from schools; and 3) insufficient availability of school nurses. Parents were significantly more likely to successfully complete the reporting process if they knew about special accommodations for chronic diseases, understood the need for physician verification, and/or knew the school nurse.
CONCLUSIONS: These findings suggest that increasing parental knowledge of the reporting process will allow schools to better identify and manage their students’ chronic conditions. A parent-focused intervention informed by these results has been completed.
PMID: 25481628 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Identifying infants at high risk of peanut allergy: The Learning Early About Peanut Allergy (LEAP) screening study.
| Related Articles |
Identifying infants at high risk of peanut allergy: The Learning Early About Peanut Allergy (LEAP) screening study.
J Allergy Clin Immunol. 2012 Nov 19;
Authors: Du Toit G, Roberts G, Sayre PH, Plaut M, Bahnson HT, Mitchell H, Radulovic S, Chan S, Fox A, Turcanu V, Lack G, Learning Early About Peanut Allergy (LEAP) Study Team
Abstract
BACKGROUND: Peanut allergy (PA) is rare in countries in which peanuts are introduced early into infants’ diets. Learning Early About Peanut Allergy (LEAP) is an interventional study aiming to assess whether PA can be prevented by oral tolerance induction. OBJECTIVE: We sought to characterize a population screened for the risk of PA. METHODS: Subjects screened for the LEAP interventional trial comprise the LEAP screening study cohort. Infants were aged 4 to 10 months and passed a prescreening questionnaire. RESULTS: This analysis includes 834 infants (mean age, 7.8 months). They were split into the following: group I, patients with mild eczema and no egg allergy (n = 118); group II, patients with severe eczema, egg allergy, or both but 0-mm peanut skin prick test (SPT) wheal responses (n = 542); group III, patients with severe eczema, egg allergy, or both and 1- to 4-mm peanut wheal responses (n = 98); and group IV, patients with greater than 4-mm peanut wheal responses (n = 76). Unexpectedly, many (17%) in group II had peanut-specific IgE sensitization (?0.35 kU/L); 56% of group III were similarly sensitized. In contrast, none of the patients in group I and 91% of those in group IV had peanut-specific IgE sensitization. Sensitization on skin testing to peanut (SPT response of 1-4 mm vs 0 mm) was associated with egg allergy and severe eczema (odds ratio [OR], 2.31 [95% CI, 1.39-3.86] and 2.47 [95% CI, 1.14-5.34], respectively). Similar associations were observed with specific IgE sensitization. Black race was associated with a significantly higher risk of peanut-specific IgE sensitization (OR, 5.30 [95% CI, 2.85-9.86]). Paradoxically, for a given specific IgE level, black race was protective against cutaneous sensitization (OR, 0.15 [95% CI, 0.04-0.61]). CONCLUSION: Egg allergy, severe eczema, or both appear to be useful criteria for identifying high-risk infants with an intermediate level of peanut sensitization for entry into a PA prevention study. The relationship between specific IgE level and SPT sensitization needs to be considered within the context of race.
PMID: 23174658 [PubMed – as supplied by publisher]
View full post on pubmed: asthma